Advances in Mesenchymal Stem Cell Therapy for Osteoarthritis: From Preclinical and Clinical Perspectives

The prevalence of osteoarthritis (OA), a degenerative disorder of joints, has substantially increased in recent years. Its key pathogenic hallmarks include articular cartilage destruction, synovium inflammation, and bone remodeling. However, treatment outcomes are unsatisfactory. Until recently, com...

Full description

Saved in:
Bibliographic Details
Published in:Bioengineering (Basel) 2023-02, Vol.10 (2), p.195
Main Authors: Lv, Zehui, Cai, Xuejie, Bian, Yixin, Wei, Zhanqi, Zhu, Wei, Zhao, Xiuli, Weng, Xisheng
Format: Article
Language:English
Subjects:
Adipocytes
Adipose tissue
Analgesics
Apoptosis
Arthritis
Bioengineering
Body fat
Bone marrow
Bone remodeling
Cartilage
Cartilage (articular)
Cartilage diseases
cartilage regeneration
Cell therapy
Cell-mediated immunity
clinical trials
Cord blood
Dendritic cells
Gene expression
Genetic engineering
Genotype & phenotype
Growth factors
Hematopoietic stem cells
Immune system
Immunology
Inflammation
Joint diseases
Mesenchymal stem cells
Mesoderm
Osteoarthritis
preclinical trials
Review
Stem cells
Synovium
Transplantation
Tumor necrosis factor-TNF
Umbilical cord
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prevalence of osteoarthritis (OA), a degenerative disorder of joints, has substantially increased in recent years. Its key pathogenic hallmarks include articular cartilage destruction, synovium inflammation, and bone remodeling. However, treatment outcomes are unsatisfactory. Until recently, common therapy methods, such as analgesic and anti-inflammatory treatments, were aimed to treat symptoms that cannot be radically cured. Mesenchymal stem cells (MSCs), i.e., mesoderm non-hematopoietic cells separated from bone marrow, adipose tissue, umbilical cord blood, etc., have been intensively explored as an emerging technique for the treatment of OA over the last few decades. According to existing research, MSCs may limit cartilage degradation in OA by interfering with cellular immunity and secreting a number of active chemicals. This study aimed to examine the potential mechanism of MSCs in the treatment of OA and conduct a thorough review of both preclinical and clinical data.
ISSN:2306-5354
2306-5354
DOI:10.3390/bioengineering10020195